Therefore, we hypothesized that there would be crosstalk between the PAFR and EGFR pathways, which may be one of reasons for the resistance of cancer cells to drugs, and that the combined targeting of PAFR and EGFR would synergistically inhibit ovarian cancer progression. This evidence concerns the gene EGFR and ovarian carcinoma.